{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:43:52Z","timestamp":1787694232754,"version":"build-2784847793"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.critrevonc.2016.01.006","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T11:42:59Z","timestamp":1452944579000},"page":"286-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review"],"prefix":"10.1016","volume":"99","author":[{"given":"A.","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.M.","family":"Vagnildhaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.H.","family":"Gr\u00f8nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kaasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Laird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.S.","family":"Solheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2016.01.006_bib0005","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1200\/JCO.2006.07.0201","article-title":"Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0010","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2007.15.6240","article-title":"Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial\u2014SAKK 44\/00-CECOG\/PAN.1.3.001","volume":"26","author":"Bernhard","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000357965","article-title":"Clinical benefit response in pancreatic cancer trials revisited","volume":"37","author":"Bernhard","year":"2014","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0020","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.ejca.2010.07.023","article-title":"Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma","volume":"46","author":"Bonnetain","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0025","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2001.19.15.3447","article-title":"Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial","volume":"19","author":"Bramhall","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjc.6600446","article-title":"A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer","volume":"87","author":"Bramhall","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0035","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0040","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"Feb (3)","key":"10.1016\/j.critrevonc.2016.01.006_bib0045","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejca.2012.08.019","article-title":"Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials","volume":"49","author":"Ciliberto","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0050","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.ejca.2008.12.022","article-title":"A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine","volume":"45","author":"Ciuleanu","year":"2009","journal-title":"Eur. J. Cancer)"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0055","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.10323","article-title":"Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and\/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell\u2019Italia Meridionale","volume":"94","author":"Colucci","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0060","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study","volume":"28","author":"Colucci","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0065","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0070","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Cunningham","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0075","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/gut.2010.216135","article-title":"Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)","volume":"59","author":"Dahan","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0080","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdf197","article-title":"A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma","volume":"13","author":"Ducreux","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpainsymman.2008.02.007","article-title":"Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer","volume":"37","author":"Eckhardt","year":"2009","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0090","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2003.12.121","article-title":"Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials\u2014does HRQOL evaluation in prostate cancer research inform clinical decision making?","volume":"21","author":"Efficace","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/oxfordjournals.annonc.a010597","article-title":"Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective","volume":"7","author":"Gelber","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial","volume":"31","author":"Gourgou-Bourgade","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0105","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/1471-2407-14-471","article-title":"Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis","volume":"14","author":"Gresham","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0110","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/cncr.24410","article-title":"Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma","volume":"115","author":"Hattangadi","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1572-0241.2000.01699.x","article-title":"A multispecialty approach to the diagnosis and management of pancreatic cancer","volume":"95","author":"Hawes","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0120","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1200\/JCO.2005.05.1490","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer","volume":"24","author":"Heinemann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0125","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2407-8-82","article-title":"Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer","volume":"8","author":"Heinemann","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0130","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","article-title":"Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group","volume":"25","author":"Herrmann","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0135","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0140","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","article-title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","volume":"12","author":"Kindler","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0145","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1007\/s00520-006-0067-0","article-title":"Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study","volume":"14","author":"Labori","year":"2006","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0150","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/annonc\/mdr379","article-title":"Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial","volume":"23","author":"Lohr","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0155","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2002.09.029","article-title":"Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer","volume":"20","author":"Maisey","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0160","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/annonc\/mdt010","article-title":"European cancer mortality predictions for the year 2013","volume":"24","author":"Malvezzi","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0165","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2009.25.8285","article-title":"Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer","volume":"28","author":"Moinpour","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0170","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1200\/JCO.2003.02.098","article-title":"Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Moore","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0175","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000098177","article-title":"Health-related quality of life in patients with pancreatic cancer","volume":"74","author":"Muller-Nordhorn","year":"2006","journal-title":"Digestion"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0185","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/annonc\/mdi309","article-title":"A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer","volume":"16","author":"Oettle","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0190","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205","volume":"28","author":"Philip","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0195","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO.2008.20.9007","article-title":"Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Poplin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0200","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1470-2045(05)70175-3","article-title":"Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial","volume":"6","author":"Reni","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0205","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000094563","article-title":"Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial","volume":"6","author":"Reni","year":"2006","journal-title":"Pancreatology"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0210","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/annonc\/mdl081","article-title":"Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study","volume":"17","author":"Richards","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0215","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10637-009-9307-8","article-title":"Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study","volume":"29","author":"Richards","year":"2011","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0220","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.2004.12.082","article-title":"Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate","volume":"22","author":"Rocha Lima","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0225","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpainsymman.2011.09.001","article-title":"Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303)","volume":"43","author":"Romanus","year":"2012","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0230","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/oxfordjournals.annonc.a010600","article-title":"A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer","volume":"7","author":"Rothenberg","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0240","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0140-6736(08)60661-3","article-title":"Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study","volume":"371","author":"Spano","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s002689900215","article-title":"Recurrence after resection for ductal adenocarcinoma of the pancreas","volume":"21","author":"Sperti","year":"1997","journal-title":"World J. Surg."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0250","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2006.09.2551","article-title":"Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer","volume":"25","author":"Sultana","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0255","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer","volume":"22","author":"Van Cutsem","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0260","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0265","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0270","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/bjc.1997.17","article-title":"Changes in nutritional status associated with unresectable pancreatic cancer","volume":"75","author":"Wigmore","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2016.01.006_bib0275","first-page":"Cd002093","article-title":"Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer","author":"Yip","year":"2006","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816300087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816300087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:50:24Z","timestamp":1537059024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816300087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":55,"alternative-id":["S1040842816300087"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.01.006","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}